LINZESS is widely available on commercial and Medicare Part D plans
82% of patients are not required to step through an OTC to receive LINZESS*
LINZESS is a preferred or covered brand in:
10 out of10
Top Commercial plans
Top Medicare Part D plans
LINZESS is the #1 prescribed branded treatment for IBS-C and CIC
Source: IQVIA Monthly Total Prescriptions Volume data as of April 2022. Data are subject to change.
*Managed Markets Insight and Technology, LLC™, a trademark of MMIT. Database as of December 2021. Data are subject to change.
Source: MMIT data as of December 2021. Data are subject to change. Data are not a guarantee of coverage, or partial or full payment, by any payers listed. Actual benefits determined by respective plan administrators. Insurer plans, coverage criteria, and formularies are subject to change without notice. Check each patient's coverage with applicable insurers. AbbVie does not endorse any individual plans. Formulary coverage does not imply efficacy or safety.
See formulary status in your area
- Plan Name
- Plan Type
- LINZESS tier
Formulary status information is valid as of August 2022. Coverage is subject to change. Some plan clients may make independent coverage decisions. Kaiser Permanente is not included in access numbers.